Longevity Just Quietly Exited the Wellness Aisle
The third edition of The HealthIMPACT Brief, a new editorial series amplifying the conversations happening on the stages and in the hallways of healthcare’s best events.
An action plan from the Digital Health Innovation Summit for health system leaders who could not be in the room.
The previous Briefs in this series traced the integration-layer thesis across the day's investor, operator, and AI panels, as well as the two keynotes. The longevity panel deserves its own treatment because it is where the science behind the entire thesis got most concrete, and where the implications for health IT became most uncomfortable.
I caught the panel on day two of the Digital Health Innovation Summit (DHIS) at the Seaport Hotel in Boston on April 28. DHIS is a two-day event produced by Cambridge VIP. About 300 senior digital health leaders across innovators, investors, pharma, payer, and provider.
If that size and lineup sound familiar, they should. It is roughly the room we build at HealthIMPACT. Same conversation, different perspective, which is why I went.
The Business of Longevity and Healthspan Through Digital was the standout panel of the day. Stephen Klasko moderated. The panelists were Nir Barzilai of the Academy for Health and Lifespan Research, Geoff Cook of Noom, Jake Donoghue of Beacon Biosignals, and Maya Said of Outcomes4Me. They pushed each other, and the conversation was the kind I have kept replaying since I left Boston.
The official frame was longevity meets digital health. The real conversation was about longevity quitting the wellness aisle and showing up in clinical care, and what that means for the people who have to absorb it.
Aging is a pattern, not a number
Barzilai walked the room through work he co-authored with Tony Wyss-Coray's lab at Stanford. The stage version: 5,000 proteins measured in 1,000 people, biological age broken out across roughly two dozen organs. The peer-reviewed version, Oh et al. published in Nature in 2023, used plasma proteomics across 5,676 adults to estimate organ age across 11 major organs. You can be a slow ager overall and still be carrying a fast-aging brain or a fast-aging liver. Aging is not one number. It is a pattern, and the pattern tells you where to intervene.
Wyss-Coray's group has since spun this work out into a company called Teal Omics to commercialize organ-specific aging clocks. The pitch is that you can sell organ age the way 23andMe sold ancestry, except this time the answer is clinically actionable.
This panel happened the week Craig Venter died. You cannot understand the moment this science is in without understanding the bet he made in 2013.
Venter died on April 29 at 79, from side effects of treatment for a recently diagnosed cancer. The obituaries led with the genome. He raced the federal government to sequence the first human genome through his private company Celera, finishing alongside the public Human Genome Project at a White House announcement with Bill Clinton in June 2000. He went on to build the first self-replicating cell controlled by a synthetic chromosome, in 2010. He was not a quiet figure.
The piece of his career that matters for this panel is what he did next. In 2013, with Peter Diamandis and Robert Hariri, he co-founded Human Longevity Inc. The premise was that if you sequenced a person's whole genome, ran advanced clinical imaging from head to toe, profiled their blood biomarkers and metabolome, and stitched all of it together with machine learning, you could detect disease years before symptoms and reroute people onto a healthier path. The flagship product was Health Nucleus, a five-hour annual exam that generated about 150 gigabytes of data per visit. HLI raised more than $300 million.
It did not deliver on the original promise, and the reasons are precisely the problems this panel kept circling. The product was priced for the affluent, which is the equity argument Klasko pushed hardest on later in the session. The data was not actionable enough at the point of care, because the decision-support layer underneath did not exist yet. The science was not ready either. Proteomics-based organ aging clocks did not exist in 2013. Most of the continuous wearable infrastructure did not exist. And the health system was not built to absorb the output. HLI pivoted, struggled, and never turned the Health Nucleus model into routine clinical care.
Klasko told a story on stage about Venter from those years. The after-dinner question he used to ask people: if Venter was right and he came to you with a number for how many years you had left, would you want to know? People under 45 said no. People over 60 said yes.
The science Venter bet on is finally getting close. He did not get to see it land. The companies that win this round will be the ones who learned from what HLI got wrong, not the ones who just rerun his pitch with prettier dashboards.
Barzilai's best line of the day was the cleanest argument I have heard against single-fix thinking. Statins prevent you from having heart attacks, so you get Alzheimer's first.
We optimize one organ at the cost of another and call it prevention.
Donoghue made the same point from the brain side. Beacon's pitch is that sleep EEG holds the signal of brain aging. The use case he led with was not wellness. It was treatment-resistant depression. Eighty-five percent of major depression patients have sleep disturbance. Treatment is still trial and error across SSRIs while patients lose six weeks waiting to find out if a drug works. A brain-based biomarker can identify responders on night one. That is a clinical decision-support tool that happens to also tell you something about your aging brain.
His framing was the cleanest of the session. Longevity without the brain is not longevity.
GLP-1 ended the theoretical phase
Cook framed GLP-1 as the moment longevity stopped being aspirational. Novo's chief scientific officer was on stage in Copenhagen last summer calling semaglutide longevity medicine. A Boston study Barzilai cited showed GLP-1s in patients with diabetes plus heart failure with preserved ejection fraction cut hospitalization and death by close to 60 percent in a year. Roughly $30,000 saved per prevented ICU day.
Then the catch. Most people stop taking it. Prime Therapeutics tracked patients on GLP-1s for weight loss over three years and found only 1 in 12 were still on the drug. Real-world data more broadly shows about half discontinue within the first 12 months. Cost. Side effects. Human nature.
That gap is the business. Cook's argument for Noom is that behavior change paired to the drug fills the window the medication opens. The bigger argument is the convergence story. Clinical care, pharmacy, blood diagnostics, wearables, and behavior are merging into one workflow. Nobody has built the integration layer. Someone has to.
The equity problem is the business model problem
Klasko pushed hardest here. Most longevity companies sell to the self-motivated, educated, and affluent. People who were going to be fine. The bottom 50 percent of the income distribution, which is where healthcare is actually struggling, gets none of it.
Said's answer was the one I keep thinking about. Internal reform of the system has stalled. The rewiring is going to come from the consumer side, through freemium and premium models that pressure incumbents the way they have in every adjacent tech category.
Barzilai went concrete. Metformin is generic, cheap, and probably adds two to three years of healthspan on average. The cheapest drug in the formulary may also be one of the most consequential anti-aging interventions we have. We just do not prescribe it that way.
The Klasko line that got the room laughing was also a real argument. Claude Opus 4.7 understands me better than anybody other than my wife.
He was talking about how his wearables, sleep scores, supplement stacks, and fragmented apps know more about him than his doctor does. AI assistants are filling the integration gap because the system did not. That is not a flex on AI. That is an indictment of the workflow.
What this means if you run health IT
Longevity is not a separate category from chronic care anymore. The data infrastructure to do it well is the data infrastructure to do prevention well. Continuous monitoring, organ-level biomarkers, and pharmacological intervention are converging into one workflow, and most EHRs were not built for it.
Brain health data is going to show up in your environment whether you plan for it or not. Patients are walking in with Apple Watch sleep stages and asking clinicians what they mean. The clinicians cannot interpret it. The AI assistants in your environment do not have the underlying brainwave signal to help. Somebody is going to fill that gap.
The GLP-1 persistence problem is going to land on care teams, not on pharma. Eighteen-month discontinuation curves mean somebody has to build the wraparound. Coaching, monitoring, behavioral support. Reimbursement for it is not figured out.
The lightning round closed with each panelist describing the longevity company that matters in 2031. Behavior change at scale. One app that carries you through life. Cognition threaded through every other data set about you.
None of those are wellness companies. They are clinical infrastructure companies that have not been built yet.
Klasko closed the panel with a Jason Kidd line. When Kidd got traded to the Mavericks, he promised to turn the team around 360 degrees. Klasko's point: forty years in healthcare, plenty of 360-degree turns, never an actual corner. He said this panel felt like an actual corner. I left Boston thinking he was right.
This Brief closes the four-part series on day two of the Digital Health Innovation Summit. The conversation continues at the HealthIMPACT Fall Forum in October and on the Digital Health Talks Podcast.
Day two of the Digital Health Innovation Summit (DHIS), a two-day event from Cambridge VIP, Seaport Hotel, Boston, April 28.
HealthIMPACT Briefs are insights from healthcare conferences, our own and others, written for the C-suite leaders who could not be in the room.
HealthIMPACT Live convenes the rooms where health system C-suite technology leaders solve this work together. The Operators Table dinner series, the HealthIMPACT Fall Forum, and the Digital Health Talks Podcast. Subscribe to the newsletter at healthimpactlive.com.
